Stratos Investment Management’s Grace Therapeutics GRCE Stock Holding History

Stratos Investment Management’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$25.3K	Buy	+11,158	New	+$30.9K	﹤0.01%	382

Other funds holding GRCE

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Maven Securities St Helier, Jersey $5.06B AUM 59.27% 1-Year Est. Return

Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return

Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Stratos Investment Management's GRCE Position: Q2 2026 in Review

Stratos Investment Management opened a new position in Grace Therapeutics (GRCE) in Q2 2026: 11,158 shares worth $25.3K. The stake represents ﹤0.01% of the portfolio and ranks #382 among its holdings.

33 funds tracked by Wall St. Rank hold GRCE as of Q2 2026.

Stratos Investment Management held 11,158 shares of Grace Therapeutics worth $25.3K as of Q2 2026.
Grace Therapeutics was a new Stratos Investment Management position in Q2 2026.
Grace Therapeutics made up ﹤0.01% of Stratos Investment Management's portfolio in Q2 2026, its #382 holding.
33 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2026.

Based on Stratos Investment Management's 13F filing for Q2 2026, filed 11 Aug 2026.